Results 91 to 100 of about 768 (176)

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis. [PDF]

Neurol Neuroimmunol Neuroinflamm, 2023
Hauser SL, Bar-Or A, Weber MS, Kletzl H, Günther A, Manfrini M, Model F, Mercier F, Petry C, Wing Q, Koendgen H, Smith T, Kappos L.   +12 more
europepmc   +1 more source

Does Ocrelizumab Limit Multiple Sclerosis Progression? Current Evidence from Clinical, MRI, and Fluid Biomarkers. [PDF]

Neurotherapeutics, 2022
Margoni M, Preziosa P, Tortorella P, Filippi M, Rocca MA.   +4 more
europepmc   +1 more source

Ocrelizumab-induced acute pancreatitis: case report of an uncommon side effect of multiple sclerosis treatment. [PDF]

Int J Surg Case Rep
Hanna S, Selvendran S.
europepmc   +1 more source

Societal Versus Healthcare Perspectives on the Cost Effectiveness of Ocrelizumab for Treatment of Primary Progressive Multiple Sclerosis in Aotearoa New Zealand. [PDF]

Pharmacoeconomics
Milne RJ, Schousboe C, Campbell JA, Mottershead J.   +3 more
europepmc   +1 more source

Composite Confirmed Disability Worsening/Progression Is a Useful Clinical Endpoint for Multiple Sclerosis Clinical Trials. [PDF]

Neurology
Kappos L, Yiu S, Dahlke F, Coetzee T, Cutter GR, Yuen S, Bonati U, Lublin FD.   +7 more
europepmc   +1 more source

Genome-wide study of longitudinal brain imaging measures of multiple sclerosis progression across six clinical trials. [PDF]

Sci Rep, 2023
Loomis SJ, Sadhu N, Fisher E, Gafson AR, Huang Y, Yang C, Hughes EE, Marshall E, Herman A, John S, Runz H, Jia X, Bhangale T, Bronson PG.   +13 more
europepmc   +1 more source

Genetic histories of individuals from multi-faith medieval Sicily. [PDF]

PLoS One
Monnereau A, Orecchioni P, Hamilton D, Green EJ, Noble I, Hagan R, Sandoval-Velasco M, Molinari A, Carver M, Speller CF, Wales N.   +10 more
europepmc   +1 more source

Ocrelizumab reduces thalamic volume loss in patients with RMS and PPMS. [PDF]

Mult Scler, 2022
Arnold DL, Sprenger T, Bar-Or A, Wolinsky JS, Kappos L, Kolind S, Bonati U, Magon S, van Beek J, Koendgen H, Bortolami O, Bernasconi C, Gaetano L, Traboulsee A.   +13 more
europepmc   +1 more source

Short- and long-term effects of early versus delayed treatment with ocrelizumab on cerebellar volume loss in patients with RMS and PPMS. [PDF]

Mult Scler
Arnold DL, Kolind S, Assemlal HE, Bar-Or A, Inglese M, Kappos L, Parmar K, Sprenger T, Traboulsee A, Vavasour IM, Wolinsky JS, Bernasconi C, Bonati U, Magon S, Tackenberg B, Gaetano L.   +15 more
europepmc   +1 more source

Estimating individual treatment effect on disability progression in multiple sclerosis using deep learning. [PDF]

Nat Commun, 2022
Falet JR, Durso-Finley J, Nichyporuk B, Schroeter J, Bovis F, Sormani MP, Precup D, Arbel T, Arnold DL.   +8 more
europepmc   +1 more source